Definitive Technology Licensing Agreement Reached
Under the terms of the agreement and as earlier announced, the Licensee will pay a minimum of US$122,000 in pre-defined staged payments to Lexaria over the initial two-year term, which will commence in the state of Colorado. The agreement contemplates significant opportunities to expand, both in scope of products offered in Colorado as well as to other states such as California, Washington, and Oregon. As per the Agreement, if the Licensee were to introduce certain product lines utilizing Lexaria’s technology in each of the four states contemplated, for example, then Lexaria could expect to receive a maximum of $1,064,000 over approx 3 ½ years, and the Licensee would enjoy semi-exclusivity to introduce its quality products in each of those states.
The Licensee is preparing its outstanding products for the marketplace at this time, and Lexaria is further protecting competitive advantages by seeking to maintain the confidentiality of certain strategic information from the industry. Lexaria is not itself producing any products under the agreement, and instead is making its technology available to the Licensee and state-licensed partners.
Lexaria continues discussions with other companies also interested in licensing Lexaria’s absorption technology that provides for improved food consumption experiences and performance. Lexaria’s technology provides significant competitive advantages to its licensed partners, such as flavour enhancement without the use of large amounts of sweeteners; and of course, higher bioavailability both by total quantity of bioactive substance that is absorbed as well as enhancing how quickly this occurs. These advantages lead to higher quality experiences for consumers while delivering competitive advantages to companies utilizing the technology.
“We could not be more pleased to see our technology being utilized within new sectors,” said John Docherty, President of Lexaria. “Our technology enables superior experiences for customers as evidenced in in vitro testing conducted to date, and our partner is making a strong commitment to provide their customers with the very best that cutting edge science and technology can provide.”
Attorneys with expertise in intellectual property law and cannabis-specific practices have come together to create one of the first technology licensing agreements of its kind with application to cannabinoids. Lexaria Bioscience has received requests from companies located in North America, Europe, and the Caribbean related to applications for its technology for enhancing the delivery of other payload molecules including but not limited to cannabinoids and is actively evaluating other technology licensing opportunities which it will disclose in due course.
“We’ve been transparent with stakeholders as to the validity and application of our encapsulation technology and that we would leverage it with licensed partners for mutual benefit,” said Chris Bunka, CEO of Lexaria. “There is great complexity in defining and constructing precise and lasting agreements and these require thoughtful consideration. Our goal remains to place our technology in food products across America and internationally, not only within the cannabinoid food sector, but also with vitamins, NSAIDs and more, creating entirely new and unprecedented product categories.”
Lexaria’s unique patent pending technology allows for more efficient and effective absorption of certain molecules such as vitamins and cannabinoids, while simultaneously masking and at times even eliminating inherent strong flavours and/or odors typical of those molecules. Lexaria’s technology is extremely cost effective to implement and applicable to the widest imaginable spectrum of foods including but not limited to chocolates, candies, coffee, tea, a wide variety of other beverages, protein bars, cookies, pastas, entrees, breads, and much more.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com